{"slideshow_credits": null, "snippet": "The decision requires Bayer to license the drug Nexavar to Natco Pharma, which must pay Bayer a royalty on its sales but will sell the drug for about 3 percent of Bayer\u2019s price.", "abstract": "India authorizes Bayer to license its patented cancer drug Nexavar to Natco Pharma, which must pay Bayer a royalty on its generic sales but will sell the drug for about 3 percent of Bayer\u2019s price; decision could open door to a flood of other compulsory licenses in India creating a new supply of cheap generic drugs.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Vikas", "role": "reported", "lastname": "BAJAJ", "rank": 1, "organization": ""}, {"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 2, "organization": ""}], "original": "By VIKAS BAJAJ and ANDREW POLLACK", "contributor": "Andrew Pollack reported from Los Angeles."}, "web_url": "http://www.nytimes.com/2012/03/13/business/global/india-overrules-bayer-allowing-generic-drug.html", "lead_paragraph": "The decision requires Bayer to license the drug Nexavar to Natco Pharma, which must pay Bayer a royalty on its sales but will sell the drug for about 3 percent of Bayer\u2019s price.", "headline": {"seo": "India Orders Bayer to License Patented Cancer Drug", "main": "India Orders Bayer to License a Patented Drug", "print_headline": "India Orders Bayer to License a Patented Drug"}, "_id": "53f4889238f0d857ea2d1193", "word_count": "900", "multimedia": [{"height": 330, "url": "images/2012/03/13/business/Drug/Drug-articleLarge.jpg", "legacy": {"xlarge": "images/2012/03/13/business/Drug/Drug-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "330"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2012/03/13/business/Drug2/Drug2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2012/03/13/business/Drug2/Drug2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2012-03-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "India", "name": "glocations", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Suits and Litigation", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Inventions and Patents", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Cancer", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Bayer A.G", "name": "organizations", "is_major": "Y", "rank": "8"}], "blog": [], "subsection_name": "Global Business", "type_of_material": "News"}